CRC Research Update — September 05, 2026
Today's colorectal cancer research highlights
liver-mets
A collection of 55 issues
Circulating Tumor DNA Predicts Recurrence After Liver Metastasis Resection
Skip to content
The CRC Digest
◇ RESEARCH
Circulating Tumor DNA Predicts Recurrence After Liver Metastasis Resection
A systematic review and meta-analysis found that circulating tumor DNA (ctDNA) serves as a biomarker for recurrence after curative resection of colorectal cancer liver metastases, potentially guiding post-surgical surveillance strategies. (Clinical Colorectal Cancer)
This
CRC Research Update — September 02, 2026
Today's colorectal cancer research highlights
CRC Research Update — August 31, 2026
Today's colorectal cancer research highlights
Targeted m6A Demethylation of ZBTB7A Suppresses Liver Metastasis in Preclinical Models
Skip to content
The CRC Digest
Targeted m6A Demethylation of ZBTB7A Suppresses Liver Metastasis in Preclinical Models
Researchers identified ZBTB7A as an m6A-modified transcription factor that promotes colorectal cancer liver metastasis, with METTL3-mediated m6A modification of ZBTB7A facilitating recognition by the m6A reader YTHDF1/3 complex. (Molecular Cancer)
This content
CRC Research Update — August 27, 2026
Today's colorectal cancer research highlights
ctDNA Testing May Identify Who Benefits from Chemotherapy After Liver Metastasis Surgery
Skip to content
The CRC Digest
ctDNA Testing May Identify Who Benefits from Chemotherapy After Liver Metastasis Surgery
An overall survival analysis of the phase II GALAXY study presented at ESMO GI 2026 suggests that circulating tumor DNA for molecular residual disease tracking could help identify patients with colorectal cancer
CRC Research Update — August 24, 2026
Today's colorectal cancer research highlights
CRC Research Update — August 23, 2026
Today's colorectal cancer research highlights
Study compares biologic agents in liver-limited RAS wild-type disease
Skip to content
The CRC Digest
▸ TREATMENT
Study compares biologic agents in liver-limited RAS wild-type disease
A retrospective analysis of 241 patients with RAS wild-type metastatic colorectal cancer confined to the liver compared outcomes among patients treated with first-line chemotherapy plus panitumumab, cetuximab, or bevacizumab, evaluating depth of response, objective